Logo image of FTRE

FORTREA HOLDINGS INC (FTRE) Stock Fundamental Analysis

NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD

8.04  +0.14 (+1.77%)

After market: 8.04 0 (0%)

Fundamental Rating

3

Taking everything into account, FTRE scores 3 out of 10 in our fundamental rating. FTRE was compared to 54 industry peers in the Life Sciences Tools & Services industry. FTRE may be in some trouble as it scores bad on both profitability and health. FTRE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FTRE was profitable.
In the past year FTRE has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: FTRE reported negative net income in multiple years.
FTRE had a positive operating cash flow in each of the past 5 years.
FTRE Yearly Net Income VS EBIT VS OCF VS FCFFTRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

FTRE has a Return On Assets of -36.22%. This is in the lower half of the industry: FTRE underperforms 77.78% of its industry peers.
FTRE's Return On Equity of -174.29% is on the low side compared to the rest of the industry. FTRE is outperformed by 83.33% of its industry peers.
Industry RankSector Rank
ROA -36.22%
ROE -174.29%
ROIC N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
FTRE Yearly ROA, ROE, ROICFTRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

Looking at the Gross Margin, with a value of 19.73%, FTRE is doing worse than 81.48% of the companies in the same industry.
FTRE's Gross Margin has been stable in the last couple of years.
FTRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
FTRE Yearly Profit, Operating, Gross MarginsFTRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

1

2. Health

2.1 Basic Checks

FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FTRE has been increased compared to 1 year ago.
FTRE has a better debt/assets ratio than last year.
FTRE Yearly Shares OutstandingFTRE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
FTRE Yearly Total Debt VS Total AssetsFTRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 0.42, we must say that FTRE is in the distress zone and has some risk of bankruptcy.
FTRE's Altman-Z score of 0.42 is on the low side compared to the rest of the industry. FTRE is outperformed by 66.67% of its industry peers.
FTRE has a Debt/Equity ratio of 1.87. This is a high value indicating a heavy dependency on external financing.
FTRE has a worse Debt to Equity ratio (1.87) than 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC9.72%
FTRE Yearly LT Debt VS Equity VS FCFFTRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

FTRE has a Current Ratio of 1.02. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
FTRE has a Current ratio of 1.02. This is amonst the worse of the industry: FTRE underperforms 85.19% of its industry peers.
A Quick Ratio of 1.02 indicates that FTRE should not have too much problems paying its short term obligations.
FTRE's Quick ratio of 1.02 is on the low side compared to the rest of the industry. FTRE is outperformed by 81.48% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
FTRE Yearly Current Assets VS Current LiabilitesFTRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

FTRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.22%, which is quite impressive.
Looking at the last year, FTRE shows a decrease in Revenue. The Revenue has decreased by -4.96% in the last year.
Measured over the past years, FTRE shows a decrease in Revenue. The Revenue has been decreasing by -4.10% on average per year.
EPS 1Y (TTM)72.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%733.33%
Revenue 1Y (TTM)-4.96%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%7.23%

3.2 Future

FTRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.19% yearly.
The Revenue is expected to grow by 1.53% on average over the next years.
EPS Next Y40.94%
EPS Next 2Y52.2%
EPS Next 3Y46.84%
EPS Next 5Y42.19%
Revenue Next Year-6.93%
Revenue Next 2Y-3.06%
Revenue Next 3Y-0.93%
Revenue Next 5Y1.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FTRE Yearly Revenue VS EstimatesFTRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
FTRE Yearly EPS VS EstimatesFTRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

FTRE is valuated correctly with a Price/Earnings ratio of 12.97.
Compared to the rest of the industry, the Price/Earnings ratio of FTRE indicates a rather cheap valuation: FTRE is cheaper than 96.30% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.84, FTRE is valued rather cheaply.
A Price/Forward Earnings ratio of 10.21 indicates a reasonable valuation of FTRE.
98.15% of the companies in the same industry are more expensive than FTRE, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.29. FTRE is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.97
Fwd PE 10.21
FTRE Price Earnings VS Forward Price EarningsFTRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FTRE is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 222.5
FTRE Per share dataFTRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FTRE's earnings are expected to grow with 46.84% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y52.2%
EPS Next 3Y46.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FTRE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTREA HOLDINGS INC

NASDAQ:FTRE (8/15/2025, 8:24:15 PM)

After market: 8.04 0 (0%)

8.04

+0.14 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners98.83%
Inst Owner Change6.56%
Ins Owners0.22%
Ins Owner Change27.84%
Market Cap730.03M
Analysts51.25
Price Target6.2 (-22.89%)
Short Float %15.9%
Short Ratio5.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.11%
Min EPS beat(2)126.66%
Max EPS beat(2)197.56%
EPS beat(4)2
Avg EPS beat(4)65.68%
Min EPS beat(4)-51.68%
Max EPS beat(4)197.56%
EPS beat(8)3
Avg EPS beat(8)-57.12%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.8%
Min Revenue beat(2)4.96%
Max Revenue beat(2)10.63%
Revenue beat(4)2
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-2.83%
Max Revenue beat(4)10.63%
Revenue beat(8)3
Avg Revenue beat(8)-1.24%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.67%
PT rev (3m)-20.07%
EPS NQ rev (1m)1.88%
EPS NQ rev (3m)-61.34%
EPS NY rev (1m)0%
EPS NY rev (3m)5.55%
Revenue NQ rev (1m)4.68%
Revenue NQ rev (3m)-6.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.34%
Valuation
Industry RankSector Rank
PE 12.97
Fwd PE 10.21
P/S 0.27
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB N/A
EV/EBITDA 222.5
EPS(TTM)0.62
EY7.71%
EPS(NY)0.79
Fwd EY9.8%
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS30.1
BVpS6.49
TBVpS-11.35
PEG (NY)0.32
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.22%
ROE -174.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.73%
FCFM N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Debt/EBITDA 134.26
Cap/Depr 18.99%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 0.42
F-Score3
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%733.33%
EPS Next Y40.94%
EPS Next 2Y52.2%
EPS Next 3Y46.84%
EPS Next 5Y42.19%
Revenue 1Y (TTM)-4.96%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%7.23%
Revenue Next Year-6.93%
Revenue Next 2Y-3.06%
Revenue Next 3Y-0.93%
Revenue Next 5Y1.53%
EBIT growth 1Y-39.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.09%
EBIT Next 3Y8.59%
EBIT Next 5Y11.67%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A